Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter

Fortsett

Tilbake

Relvar: Dosing and pharmacology

Professor Jan Lötvall ved Universitetet i Gøteborg, Krefting Research Centre, gjennomgår dosering og de farmakologiske data for virkestoffene i Relvar: Flutikasonfuroat, et langtidsvirkende inhalasjonsstereoid (ICS) og vilanterol, en langtidsvirkende beta2-agonist (LABA).

Video player requires JavaScript enabled. You can download this video here: http://gskvideo.edgesuite.net/HealthSites/Health/Norway/HCP/MP4/lotvall-relvar-pharmacology.mp4

Aktuell litteratur

  1. Bateman ED, Bleecker ER, Lötvall J, Woodcock A, Forth R, Medley H, Davis AM, Jacques L, Haumann B, Busse WW. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012;106(5):642-50. [Pubmed]
  2. Biggadike K. Fluticasone furoate/fluticasone propionate - different drugs with different properties. Clin Respir J. 2011;5(3):183-4 (letter to editor). [Fulltekst]
  3. Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem. 2008;51(12):3349-52. [Pubmed]
  4. Bleecker ER, Bateman ED, Busse WW et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol. 2012;109(5):353-358. [Pubmed]
  5. Busse WW, O'Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥ 12 years old with asthma: a randomised trial. Thorax. 2013;68(6):513-20. [Pubmed]
  6. Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119-27. [Pubmed]
  7. Harrell AW, Siederer SK, Bal J, Patel NH, Young GC, Felgate CC, Pearce SJ, Roberts AD, Beaumont C, Emmons AJ, Pereira AI, Kempsford RD. Metabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013;41(1):89-100. [Pubmed]
  8. Kempsford RD, Oliver A, Bal J, Tombs L, Quinn D. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respir Med. 2013;107(12):1873-80. [Pubmed]
  9. Lötvall J, Bateman ED, Bleecker ER, Busse WW, Woodcock A, Follows R, Lim J, Stone S, Jacques L, Haumann B. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J. 2012;40(3):570-9. [Pubmed]
  10. Oliver A, Bjermer L, Quinn D, Saggu P, Thomas P, Yarnall K, Lötvall J.Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013;68(9):1136-42. [Pubmed] [Fulltekst]
  11. Relvar preparatomtale
  12. Rossios C, To Y, To M, Ito M, Barnes PJ. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011;670(1):244-51. [Pubmed]
  13. Valotis A et al. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Resp Res. 2007; 8: 54. [Pubmed]
  14. Relvar Felleskatalogtekst

Relvar og Ellipta er registrerte varemerker av GSK group of companies

Relvar Ellipta er utviklet i samarbeid med Innoviva Inc.